Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease
✍ Scribed by Irune Cariñanos; Manuel Barreiro-De Acosta; Eugeni Domènech
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 50 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
PG) is an uncommon neutrophilic dermatosis first described by Brunsting et al in 1930. 1 It is a painful, chronic ulcerating inflammatory skin condition that appears to be immune-mediated. The characteristic lesion begins as small erythematous papules that rapidly spread concentrically, coalesce, an
The conventional treatment of inflammatory bowel disease (IBD) has focused on nonspecifically targeting mucosal inflammation. In the last decade, with the advent of novel biological agents that directly inhibit proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-a), rapid progress ha
Background: Abnormal host-microbe interactions are implicated in the pathogenesis of inflammatory bowel diseases. Previous 16S rRNA sequence analysis of intestinal tissues demonstrated that a subset of Crohn's disease (CD) and ulcerative colitis (UC) samples exhibited altered intestinal-associated m
## Background: The pathogenesis of inflammatory bowel disease (ibd) involves the interaction between genetic susceptibility, mucosal immunity, and intestinal bacteria. bacterial translocation is a common event in these patients and plays an important role in the perpetuation of chronic intestinal i